Pushpa Singh, PhD

Dr. Singh is a Pharmaceutical R&D executive with over 30+ years of experience in all phases of product development including discovery, development, technology transfer, and product life-cycle management. As a Vice President, Quality Operations & CMC Regulatory at Keryx Biopharmaceuticals, she was responsible for the overall strategic and operational activities in ensuring quality and regulatory […]

Robert Guttendorf, PhD

Dr. Guttendorf has over 25 years of experience directing preclinical and clinical DMPK programs, including regulatory interactions, in large pharmaceutical and small biotech companies. He has directed ADME/PK/Clinical Pharmacology from discovery through NDA, across therapeutic areas, with numerous regulatory submissions. He held leadership positions at Parke-Davis and Pfizer, and most recently was Vice President at Advancis […]

Aaron Mathias

Aaron Mathias has been working at Thetis since 2016. Prior to joining, he was a life science strategy consultant at the Monitor Group (Deloitte Consulting), where he focused on R&D strategy, project management and analytics in the pharmaceutical industry. He is currently a master’s student in biomedical engineering at Yale University.

Michael Van Zandt, PhD

Dr. Van Zandt is an accomplished synthetic organic and medicinal chemist with more than 20 years of experience in large and small pharmaceutical company environments. Before founding New England Discovery Partners through which he supports Thetis, Michael was a department head for The Institute for Pharmaceutical Discovery (IPD), where he co-led the aldose reductase project […]

Brian E. Harvey, MD, PhD

Dr. Brian Harvey has extensive industry, regulatory and clinical expertise in gastrointestinal and liver diseases. He previously was Vice President of U.S. Regulatory Strategy at Pfizer (2012-2015) and Vice President of U.S. Regulatory Policy at Sanofi Aventis (2007-2012). Prior to joining industry, Dr. Harvey worked at the U.S. Food & Drug Administration, most recently as […]